In the Keynote 042 trial, patients who had previously untreated advanced NSCLC with PD-L1 expression in at least 50% of tumor cells and EGFR, ALK negative, were randomized to receive in first-line treatment either pembrolizumab or the investigator’s choice of platinum-based CT. Here, ALK is linked to neoplasm.